Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Ophthalmic drug and device maker Alcon (ACL) eyes big returns from a pair of deals it signed over the past two months. Both transactions are designed to boost Alcon's presence in the treatment of age-related macular degeneration, or AMD. Full Article at Investor's Business Daily